P2141054
P2140975
P2140946
Our staff at the annual HIV conferecne 2018
Interactive board games for drug education created by Gang Saa
20190528_190528_0018
Radio program
resize
P5290378
World AIDS Day event 2018 at Maharaj Hospital
logo_edited.jpg

With 27 years of experience in conducting HIV research including HIV vaccine, HIV biomedical prevention

and treatment in various populations to develop academic knowledge on HIV / AIDS,

we have worked in collaboration with leading international research networks and other domestic agencies.

Our diverse research programs are up-to-date with present situation and necessity of knowledge both nationally and globally

We are ready to expand our field of expertise to other challenging infectious diseases and substance use

​

News and Activities

To find more information, click the image

December 2020
The article entitled "Online Drug Marketing" written by Kanittha Thaikla, head of Substance Unit, was published on ASEAN Drug Monitoring Report 2019
December 1, 2020
The US NIH announced its next seven-year HIV research grants to 35 CTUs worldwide. RIHES, in collaboration with the Thai Red Cross AIDS Research Center as the Thai CTU, has continued to receive the grant for the third round.
December 1, 2020
World AIDS Day event, End AIDS by 2030
December 1, 2020
Community Relation Unit newsletter October-December 2020 has been issued.
Click the image to read more
November 25, 2020
Prof. Suwanna Arunpongpaisal, M.D., Department of Psychiatry, Faculty of Medicine, Khon Kaen University was receiving “Alcohol in Safe City” from Knittha Thaikla, head of substance abuse unit at the 11th National Alcohol Conference.
November 25, 2020
Kanittha Thaikla, head of the substance abuse unit was a speaker at the 11th National Alhohol Conference
Photo and news by komchadluek
November 02, 2020
Welcome new collaborative research teams from the C-free project, Raks Thai Foundation, Thai Drug Users' Network and Ozone Foundation at the site initiation meeting at RIHES main building
October 08 and October 22, 2020
The HPTN 083 study team visited the Caremat Health Center and Mplus foundation, community based organizations actively working on HIV prevention for MSMs/TGs and adolescents
Survey Results
Online Alcohol Sales during COVID-19 pandemic
Show More

Research Studies Currently Underway

To learn more, click Study title (to visit webpage) or Study snapshot (in Thai)

Contact Us

Research Institute for Health Sciences, Chiang Mai University
110 Intavaroros Road, Sriphum, Muang
Chiang Mai 50200 THAILAND
Tel. 66 5393 6148

Hepatitis B virus (HBV) vaccine .jpg
Nurse Checking Girl
RSV- Respiratory Syncytial Virus acronym

The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are naïve to HBV vaccination.

Study vaccines: HEPLISAV-B vs. Engerix-B

What the body of children under 12 years of age living with HIV do to these drugs?

Are they safe for this population?

​

Abacavir/Dolutegravir/Lamivudine Dispersible and

Abacavir/Dolutegravir/Lamivudine Immediate Release Tablets​

​

Respiratory syncytial virus (RSV) is a common and very contagious virus that infects the respiratory tract of most children before their second birthday. At present, there is no specific treatment 

for RSV.

 

JNJ-53718678 is a novel drug and is under development for the treatment of RSV infection. This study purpose is to evaluate safety and antiviral activity of JNJ-53718678 in Children aged 28 days to 3 years with RSV infection 

​

©2019 by Research Center for Infectious Diseases and Substance Use. Proudly created with Wix.com